Healius Limited

Healius Limited (ASX: HLS) is one of Australia's leading healthcare companies, specialising in the delivery of specialty diagnostic services to consumers and their referring practitioners across the country. Founded in 1994 and originally known as Primary Health Care Limited, the Sydney-headquartered company has evolved into a streamlined, pathology-focused business following the divestiture of its Lumus Imaging business in early 2025, with pathology now accounting for over 70% of group revenue. Operating under a broad portfolio of well-known brands — including Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Agilex Biolabs, and Abbott Pathology — Healius runs an extensive network of over 100 medical laboratories and approximately 2,000 patient collection centres spanning metropolitan, regional, and remote Australia, delivering roughly 1 in every 3 pathology services in the country. Under the leadership of CEO Paul Anderson, the company reported annual revenue of approximately AUD 1.34 billion and employs around 8,000 people, maintaining its position as Australia's second-largest pathology provider.